Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Medically reviewed by Brendan Camp, MD Many people with psoriasis successfully undergo cosmetic procedures, but they should ...

Psoriasis results in long-term inflammation in the body. This inflammation stiffens and narrows the arteries, raising the ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Moreover, some infections may exacerbate or trigger psoriasis, such as strep throat ... These are good options if chlorine doesn’t aggravate your skin. Walking during the morning or evening ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

1,2 “People living with moderate-to-severe plaque psoriasis are seeking options that balance efficacy ... with icotrokinra to offer patients the unique combination of complete skin clearance and a ...